ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin Glargine

Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.

Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 9, 2005184 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only1241 open or runningphase 4since Sep 9, 2005Sep 30, 2002none ahead
Novo Nordiskits history only280 open or runningphase 4since Sep 12, 2005Oct 29, 2004none ahead
Eli Lillyits history only250 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Diabetes Care Centerits history only20 open or runningno phasesince Apr 3, 2007Apr 3, 2007none ahead
Biodelits history only10 open or runningphase 2since Oct 21, 2009Oct 21, 2009none ahead
Geropharm10 open or runningno phasesince Sep 23, 2019Sep 23, 2019none ahead
ikfe-CROits history only10 open or runningphase 4since Dec 5, 2011Dec 5, 2011none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 1since Sep 3, 2009Sep 3, 2009none ahead
Wockhardtits history only10 open or runningphase 1since May 12, 2011May 12, 2011none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Geropharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2019First study: no phase study in Clamp StudyFirst studyNCT04101383 · 42 enrolled · Russian Federation

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The one study Geropharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04101383Clamp Study · Russian Federation–CompletedFeb 16, 201842

How it is read

Names in the registry

  • “insulin glargine”, 38 entries
  • “Insulin Glargine”, 27 entries
  • “Insulin glargine”, 20 entries
  • “INSULIN GLARGINE”, 15 entries
  • “LY2963016”, 11 entries

Codes read as this program: HOE901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.